HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study
Journal of Clinical Oncology · 10.04.2025 · 43 (11) · 1337-1347
DOI: 10.1200/jco-24-01727 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.04.2025. Verfasst von John V Heymach und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Protein Kinase Inhibitors, Neoplasms. Die Arbeit wurde bisher 52-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE Human epidermal growth factor receptor 2 (HER2) alterations occur in many solid cancers, including non–small cell lung cancer (NSCLC). Beamion LUNG-1 (ClinicalTrials.gov identifier: NCT04886804 ) is assessing the safety/efficacy of zongertinib (BI 1810631), a novel HER2-selective tyrosine kinase inhibitor that spares epidermal growth factor receptor, in patients with HER2-altered solid tumors. MATERIALS AND METHODS Beamion LUNG-1 is an ongoing multicenter, multicohort phase Ia/Ib trial. Phase Ia assessed zongertinib administered twice a day (15-150 mg) or once daily (60-360 mg) in pretreated patients with various tumors, including NSCLC. Primary end points were maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs); tumor response was a secondary end point. RESULTS As of May 23, 2024, 105 patients were treated. Two DLTs occurred during the MTD evaluation period; MTD was not reached (NR). The recommended doses for expansion were 120 mg once daily and 240 mg once daily. Treatment-related adverse events (TRAEs; any/grade ≥3) occurred in 82%/10% of patients. The most common TRAEs (any/grade ≥3) included diarrhea (50%/1%), rash (16%/2%), anemia (10%/0%), decreased appetite (10%/1%), and increased alanine transaminase (10%/4%). The confirmed investigator-assessed overall response rate (ORR) across all doses/tumors was 30% (95% CI, 23 to 40); median duration of response was 12.7 months (95% CI, 6.9 to NR). In 54 patients with NSCLC, confirmed ORR was 35% (95% CI, 24 to 49). Activity was observed in patients with A775_G776insYVMA (ORR, 38%) and those who had received previous HER2-directed therapy (ORR, 28%). In patients with NSCLC receiving zongertinib once daily, median progression-free survival was 17.2 months (95% CI, 8.3 to NR). CONCLUSION Zongertinib had a manageable safety profile and demonstrated preliminary antitumor activity in patients with HER2-altered tumors, including those with HER2 -mutant NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX.
- Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
- Mary Crowley Cancer Research, Dallas, TX.
- Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
- Valkyrie Clinical Trials Inc, Los Angeles, CA.
- Boehringer Ingelheim Pharma GmbH & Co KG, Biberach an der Riss, Germany.
ORCID-Profile: John V Heymach, Minal Barve, Hai-Yan Tu, Yi-Long Wu, Kiyotaka Yoh, Noboru Yamamoto
Zitieren
APA
Heymach, J. V., Opdam, F., Barve, M., Tu, H. Y., Wu, Y. L., Berz, D., Schröter, L., Botilde, Y., Sadrolhefazi, B., Serra, J., Yoh, K., & Yamamoto, N. (2025). HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study. Journal of Clinical Oncology, 43(11), 1337-1347. https://doi.org/10.1200/jco-24-01727
Vancouver
Heymach JV, Opdam F, Barve M, Tu HY, Wu YL, Berz D, et al. HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study. Journal of Clinical Oncology. 2025;43(11):1337-1347. doi:10.1200/jco-24-01727
BibTeX
@article{Heymach2025,
author = {Heymach, John V and Opdam, Frans and Barve, Minal and Tu, Hai-Yan and Wu, Yi-Long and Berz, David and Schröter, Lukas and Botilde, Yanick and Sadrolhefazi, Behbood and Serra, Josep and Yoh, Kiyotaka and Yamamoto, Noboru},
title = {HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study},
journal = {Journal of Clinical Oncology},
year = {2025},
volume = {43},
number = {11},
pages = {1337--1347},
doi = {10.1200/jco-24-01727}
}
EUVIMED